Neoadjuvant ICI outperforms adjuvant delivery in many cancer types but has only been tested using single-agent anti-PD-1 in small numbers of heavily pretreated (corticosteroids and chemoradiotherapy) patients with recurrent GBM10–13 (Extended Data Table 1). This evidence concerns the gene PDCD1 and cancer.